目前,临床上应用针对结直肠癌靶向治疗的单抗药物主要包括贝伐单抗(bevacizumab,Avastin )、西妥昔单抗(cetuximab,Erbitux )和正在研究中的Panitumumab等。伊立替康作为一种对结直肠癌有明显抗肿瘤活性的细胞毒性药物,在联合单克隆抗体的研究中首先获得了突破,并迅速 At present, the monoclonal antibody drugs targeting the targeted therapy of colorectal cancer mainly include bevacizumab (Avastin), cetuximab (Erbitux) and Panitumumab under study. Irinotecan, a cytotoxic drug with significant anti-tumor activity on colorectal cancer, first achieved a breakthrough in the study of combined monoclonal antibodies and rapidly